Literature DB >> 26076707

Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice.

Kristin N Heller1,2, Chrystal L Montgomery1,2, Kimberly M Shontz1,2, K Reed Clark1,2, Jerry R Mendell1,2, Louise R Rodino-Klapac1,2.   

Abstract

Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene. It is the most common, severe childhood form of muscular dystrophy. We investigated an alternative to dystrophin replacement by overexpressing ITGA7 using adeno-associated virus (AAV) delivery. ITGA7 is a laminin receptor in skeletal muscle that, like the dystrophin-glycoprotein complex, links the extracellular matrix to the internal actin cytoskeleton. ITGA7 is expressed in DMD patients and overexpression does not elicit an immune response to the transgene. We delivered rAAVrh.74.MCK.ITGA7 systemically at 5-7 days of age to the mdx/utrn(-/-) mouse deficient for dystrophin and utrophin, a severe mouse model of DMD. At 8 weeks postinjection, widespread expression of ITGA7 was observed at the sarcolemma of multiple muscle groups following gene transfer. The increased expression of ITGA7 significantly extended longevity and reduced common features of the mdx/utrn(-/-) mouse, including kyphosis. Overexpression of α7 expression protected against loss of force following contraction-induced damage and increased specific force in the diaphragm and EDL muscles 8 weeks after gene transfer. Taken together, these results further support the use of α7 integrin as a potential therapy for DMD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26076707      PMCID: PMC4630797          DOI: 10.1089/hum.2015.062

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

1.  Muscle-specific activity of the skeletal troponin I promoter requires interaction between upstream regulatory sequences and elements contained within the first transcribed exon.

Authors:  W Nikovits; J H Mar; C P Ordahl
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

2.  Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.

Authors:  K Yuasa; M Sakamoto; Y Miyagoe-Suzuki; A Tanouchi; H Yamamoto; J Li; J S Chamberlain; X Xiao; S Takeda
Journal:  Gene Ther       Date:  2002-12       Impact factor: 5.250

3.  Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.

Authors:  A E Deconinck; J A Rafael; J A Skinner; S C Brown; A C Potter; L Metzinger; D J Watt; J G Dickson; J M Tinsley; K E Davies
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

4.  E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice.

Authors:  M A Shield; H S Haugen; C H Clegg; S D Hauschka
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

5.  Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime.

Authors:  L A Mulieri; G Hasenfuss; F Ittleman; E M Blanchard; N R Alpert
Journal:  Circ Res       Date:  1989-11       Impact factor: 17.367

6.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.

Authors:  P Sicinski; Y Geng; A S Ryder-Cook; E A Barnard; M G Darlison; P J Barnard
Journal:  Science       Date:  1989-06-30       Impact factor: 47.728

7.  Progression of kyphosis in mdx mice.

Authors:  Nicola Laws; Andrew Hoey
Journal:  J Appl Physiol (1985)       Date:  2004-07-02

8.  The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy.

Authors:  H H Stedman; H L Sweeney; J B Shrager; H C Maguire; R A Panettieri; B Petrof; M Narusawa; J M Leferovich; J T Sladky; A M Kelly
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

9.  Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R Moxley; J P Miller; M A Province
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

10.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.

Authors:  J R Mendell; R T Moxley; R C Griggs; M H Brooke; G M Fenichel; J P Miller; W King; L Signore; S Pandya; J Florence
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

View more
  9 in total

1.  Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Tatiana M Fontelonga; Brennan Jordan; Andreia M Nunes; Pamela Barraza-Flores; Nicholas Bolden; Ryan D Wuebbles; Lesley Mathews Griner; Xin Hu; Marc Ferrer; Juan Marugan; Noel Southall; Dean J Burkin
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.

Authors:  Suriyan Ponnusamy; Ryan D Sullivan; Dahui You; Nadeem Zafar; Chuan He Yang; Thirumagal Thiyagarajan; Daniel L Johnson; Maron L Barrett; Nikki J Koehler; Mayra Star; Erin J Stephenson; Dave Bridges; Stephania A Cormier; Lawrence M Pfeffer; Ramesh Narayanan
Journal:  Hum Mol Genet       Date:  2017-07-01       Impact factor: 6.150

Review 3.  Organization, dynamics and mechanoregulation of integrin-mediated cell-ECM adhesions.

Authors:  Pakorn Kanchanawong; David A Calderwood
Journal:  Nat Rev Mol Cell Biol       Date:  2022-09-27       Impact factor: 113.915

Review 4.  Breathing in Duchenne muscular dystrophy: translation to therapy.

Authors:  Doreen Z Mhandire; David P Burns; Angela L Roger; Ken D O'Halloran; Mai K ElMallah
Journal:  J Physiol       Date:  2022-06-24       Impact factor: 6.228

5.  Association between Decreased ITGA7 Levels and Increased Muscle α-Synuclein in an MPTP-Induced Mouse Model of Parkinson's Disease.

Authors:  Sangeun Han; Sabina Lim; Sujung Yeo
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

6.  Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.

Authors:  Yongping Yue; Ibrahim M Binalsheikh; Stacey B Leach; Timothy L Domeier; Dongsheng Duan
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-17       Impact factor: 0.694

Review 7.  Progress and prospects of gene therapy clinical trials for the muscular dystrophies.

Authors:  Niclas E Bengtsson; Jane T Seto; John K Hall; Jeffrey S Chamberlain; Guy L Odom
Journal:  Hum Mol Genet       Date:  2015-10-08       Impact factor: 6.150

8.  Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery.

Authors:  Jianzhong Ai; Jia Li; Dominic J Gessler; Qin Su; Qiang Wei; Hong Li; Guangping Gao
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

9.  Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Rachael A Potter; Danielle A Griffin; Kristin N Heller; Ellyn L Peterson; Emma K Clark; Jerry R Mendell; Louise R Rodino-Klapac
Journal:  Hum Gene Ther       Date:  2021-02-18       Impact factor: 5.695

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.